🔥 HOT TOPIC in #HEPATOLOGY
This landmark study shows that vibration-controlled transient elastography provides prognostic accuracy comparable to histology in #MASLD, supporting liver stiffness measurement as a noninvasive surrogate endpoint for clinical trials.
📗Read more: https://bit.ly/4c7gulx
🚨Liver lovers alert -> Just 7 weeks to go for #BavenoVIII ‼️
🗓️ 27–28 March 2026 (👶 Pediatric Symposium: 29 March)
📍 Baveno, Italy
🌐 Hybrid format — join in person or online
🔗 baveno8.org/registration
Don’t miss it! Programme 👇
Cardiogenic Shock | New England Journal of Medicine www.nejm.org/doi/full/10....
The Society of Vascular and Interventional Neurology 2025 Annual Meeting Original Article | NOV 21, 2025 | NEJM.org Medical Management and Revascularization for Asymptomatic Carotid Stenosis Figure 2A. Primary-Outcome Analysis. The NEJM signature sits at the bottom.
Presented at #SVIN25:
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?
🖇️: rdcu.be/eLAde
#LiverSky @georg-semmler.bsky.social
Review Article Noninvasive Assessment of Liver Fibrosis Laurent Castera, M.D., Ph.D., Mary E. Rinella, M.D., and Emmanuel A. Tsochatzis, M.D., Ph.D. A figure showing the diagnosis, staging, and progression of liver fibrosis. The NEJM identity sits at the bottom.
The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which the authors review. Learn more: nej.md/4hwZMgj
#MedSky #GastroSky
New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
www.thelancet.com/journals/lan...
#GastroSky #MedSky
„Beim Teutates“ #asterix41 - Asterix in Lusitanien - #outnow
Exzellenter Kommentar zur Absetzung von Late-Night-Host Jimmy Kimmel - und wie die Trump-Regierung Redefreiheit interpretiert: „Conservatives can say what they want, and everyone else can say what conservatives want.“
Review Article Metabolic Dysfunction–Associated Steatotic Liver Disease Giovanni Targher, M.D., Luca Valenti, M.D., and Christopher D. Byrne, M.B., Ch.B. Panel A: Factors related to insulin resistance and metabolic dysfunction, diet and environmental exposures, and genetic and epigenetic factors are the main drivers of MASLD development and its progression throughout the entire spectrum of liver disease. Panel B: Female sex and hormonal factors can also modulate the development and progression of MASLD.
MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular–renal–metabolic issues. Learn more: nej.md/4lpS4F0
#MedSky #Nephrology
Study by our #Liver #Team @meduniwien.ac.at
and @MedHochschuleHannover
Minimal residual ascites 3 months after #TIPS implantation implicates worse clinical outcome in patients with #liver #cirrhosis
published in @jhepatology.bsky.social #Reports
🔗 sciencedirect.com/science/arti...
Carvedilol preferred NSBB in PHT
• Reduces vascular resistance too
• Start: 6.25 mg once daily
• Titrate to 6.25 mg BID
• Max dose: 12.5 mg/day
• Maintain SBP ≥90 mmHg
• No endoscopy if on therapy
#DDW25
The New England Journal of Medicine Intensive Blood-Pressure Control in Patients with Type 2 Diabetes A Research Summary based on Bi Y et al. | 10.1056/NEJMoa2412006 | Published on November 16, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd
#MedSky #CardioSky
![Cover of the March 29, 2025 issue of The Lancet. Quote on cover reads: “Our findings show the potential for low-cost or no-cost behavioural interventions to increase participation in screening and reduce deaths from colorectal cancer [by] adding one sentence to the invitation letter.”](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ypu6bwefbbzhcvojdj7mz657/bafkreiagkucwtre7ywn3o4sbds7loqvbyrtnjuysv2bigcd4lxkzzn5jkq)
Cover of the March 29, 2025 issue of The Lancet. Quote on cover reads: “Our findings show the potential for low-cost or no-cost behavioural interventions to increase participation in screening and reduce deaths from colorectal cancer [by] adding one sentence to the invitation letter.”
Understanding colorectal cancer screening behaviour is key to increasing uptake.
In our latest issue, a recent trial evaluates the impact of two behavioural interventions on uptake of FIT colorectal screening.
Find this & more 👉 tinyurl.com/y9sjj4hc
In #CTGjournal:
Secondary SBP Prophylaxis is Associated with a Higher Rate of Non-SBP Infections in Two US-based National Cirrhosis Cohorts
Silvey, et al.
➡️ bit.ly/428BEKH
@jasmohanbajaj.bsky.social
Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis.
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
Our latest clinical practice update offers 1️⃣1️⃣ tips to help you evaluate and manage portal vein thrombosis in cirrhosis patients. Watch @drjessicadavis.bsky.social and Fadi Francis discuss management strategies. https://buff.ly/40Y66Wc
#Cirrhosis #Liversky
Der offizielle X-Account des Weißen Hauses heute Abend.
Es wird praktisch stündlich irrer.
Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)
Figure showing therapies in alcohol use disorder and their neurobiological basis. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Over 400 million people globally are affected by alcohol use disorder.
In @lancetgastrohep.bsky.social, a new Review explores the current management and treatment options for alcohol use disorder from a gastroenterology and hepatology-focused perspective: tinyurl.com/43fxj63f
